文献速递妇科生殖医学

曲贝替定联合聚乙二醇脂质体多柔比星治疗复发性卵巢癌的3期随机开放多中心试验

A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2020-01-08

这项3期试验将576例铂敏感复发性卵巢癌患者随机分配至曲贝替定联合聚乙二醇脂质体多柔比星组或单药组,主要终点总生存期无显著差异,但联合组客观缓解率更高,BRCA1/2突变及铂类无治疗间期6-12个月亚组显示生存获益。

要点

  • 联合组与单药组中位OS分别为23.8个月和22.2个月,无显著差异。
  • 联合组客观缓解率46%优于单药组35.9%,差异有统计学意义。
  • BRCA1/2突变患者联合组中位OS达34.2个月,显著优于单药组20.9个月。

核心结论

  • 曲贝替定联合聚乙二醇脂质体多柔比星未显示总生存获益且安全性更差,但BRCA1/2突变和/或PFI 6-12个月患者可能获得临床相关生存获益。

研究设计与样本

  • 3期随机、开放标签、多中心试验,纳入576例铂敏感复发性卵巢癌患者,按1:1随机分配至联合组(289例)或单药组(287例)。

主要发现

  • 联合组中位OS 23.8个月 vs 单药组22.2个月(HR 0.92,95%CI 0.73-1.18;p=0.52)。
  • 联合组中位PFS 7.52个月 vs 单药组7.26个月(HR 0.93,95%CI 0.76-1.15;p=0.52)。
  • 联合组ORR 46% vs 单药组35.9%(OR 1.52,95%CI 1.07-2.16;p=0.01)。
  • BRCA1/2突变患者联合组中位OS 34.2个月 vs 单药组20.9个月(HR 0.54,95%CI 0.33-0.90;p=0.016)。
  • BRCA1/2突变且PFI 6-12个月患者联合组中位OS 31.5个月 vs 单药组14.9个月(HR 0.37,95%CI 0.17-0.82;p=0.011)。

关键数值与推荐

  • 联合组3-4级不良事件发生率79%,单药组54%。
  • BRCA1/2突变患者联合组中位PFS 10.1个月 vs 单药组7.6个月(HR 0.72,95%CI 0.48-1.08;p=0.039)。

临床怎么用

  • 对于铂敏感复发性卵巢癌,联合方案未改善总体人群OS且毒性增加,不推荐常规使用。
  • BRCA1/2突变和/或PFI 6-12个月患者可考虑曲贝替定联合聚乙二醇脂质体多柔比星以获取生存获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This phase 3 study aimed to compare overall survival (OS) of women with platinum-sensitive, recurrent ovarian cancer (ROC) treated with third-line trabectedin (T) + pegylated liposomal doxorubicin (PLD) vs. PLD monotherapy. METHODS: Women with advanced-relapsed epithelial ovarian cancer were randomly assigned 1: 1 to intravenous infusions of either T + PLD (trabectedin 1.1 mg/m2 for 3 h; PLD 30 mg/m2 for 1.5 h, every 3 weeks) or PLD (50 mg/m2 for 1.5 h, every 4 weeks). Primary endpoint was OS. Secondary endpoints included investigator-assessed progression free survival (PFS) and objective response rates (ORR). At randomization, patients were stratified by time from last dose of first-line platinum therapy to disease progression, ECOG grade 0 or 1, BRCA1/2 germline mutational status, and prior PLD therapy. Exploratory endpoints included OS, PFS, and ORR in the stratified subgroups (PFI, ECOG, BRCA1/2 status, and prior PLD therapy). This trial is registered with ClinicalTrials.gov, number NCT01846611. RESULTS: 576 patients were randomized (T + PLD, n = 289; PLD, n = 287). Median OS was 23.8 months with T + PLD vs. 22.2 months with PLD (HR:0.92, 95%CI:0.73-1.18; p = 0.52). Median PFS was 7.52 vs. 7.26 months (HR:0.93, 95%CI:0.76-1.15; p = 0.52); ORR was 46% vs. 35.9% (OR:1.52, 95%CI:1.07-2.16; p = 0.01). Patients with BRCA1/2 mutations had median OS of 34.2 months with T + PLD vs. 20.9 months with PLD (HR:0.54, 95%CI:0.33-0.90; p = 0.016). Patients with BRCA1/2 mutations had median PFS of 10.1 months with T + PLD vs. 7.6 months with PLD (HR:0.72, 95%CI:0.48-1.08; p = 0.039). Patients with BRCA1/2 mutations and a 6-12 months platinum-free interval (PFI), median OS was 31.5 vs. 14.9 months, respectively (HR:0.37, 95%CI:0.17-0.82; p = 0.011). Grade 3-4 AEs were higher in T + PLD (79%) vs. PLD (54%). CONCLUSION: Combination of T and PLD did not show favorable OS benefit nor safety; however, patients with germline BRCA1/2 mutations and/or a PFI of 6-12 months appear to have clinically relevant survival benefit with T + PLD. No new safety signals were identified.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Monk BJ, Herzog TJ, Wang G, et al. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer. Gynecol Oncol. 2020. PMID: 31924332. doi:10.1016/j.ygyno.2019.12.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。